This study is being done to answer the following question: Which of two treatment combinations, Gemcitabine and Nab-paclitaxel or 5-Fluorouracil, Leucovorin, and Liposomal Irinotecan, is more effective at lengthening the period of time that less fit patients over the age of 70 years with metastatic pancreatic cancer (mPCA) live? We are doing this study because we want to find out what the best approach to lengthen the lives of "vulnerable" patients over the age of 70 with mPCA is. Currently, there is no known best practice for this type of patient.
Comparing Two Treatment Combinations for Older Patients With Pancreatic Cancer That Has Spread
Drexel Town Center
Froedtert Menomonee Falls Hospital
Froedtert West Bend Hospital
OPEN TO ACCRUAL